Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice

INTRODUCTION: Current therapy for Alzheimer's disease (AD) focuses on delaying progression, illustrating the need for more effective therapeutic targets. Histone deacetylase 6 (HDAC6) modulates tubulin acetylation and has been implicated as an attractive target. HDAC6 is also elevated in postmo...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Alzheimers Dement (N Y)
Главные авторы: Majid, Tabassum, Griffin, Deric, Criss, Zachary, Jarpe, Matthew, Pautler, Robia G.
Формат: Artigo
Язык:Inglês
Опубликовано: Elsevier 2015
Предметы:
Featured Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5975056/
https://ncbi.nlm.nih.gov/pubmed/29854936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2015.08.001
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы